BTAI ▼ -45.8% - BioXcel Therapeutics, Inc. $BTAI files for bankruptcy. Asset sale agreement with TEVA BioXcel Therapeutics filed for bankruptcy today and agreed to sell its assets to Teva Pharmaceuticals, triggering a 45.8% decline in its stock price. The bankruptcy filing and asset sale typically result in significant losses for existing shareholders, as they are last in line to recover value after creditors and other obligations are paid. The stock's sharp drop reflects the reality that current shareholders face substantial dilution or total loss of their investment under the restructuring. 28-AUG-2026 06:11 AM ET